BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38498297)

  • 1. Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.
    Palermo M; D'Elia C; Trenti E; Comploj E; Mian C; Schwienbacher C; Heidegger I; Clauser S; Pycha A; Vjaters E
    Minerva Urol Nephrol; 2024 Apr; 76(2):195-202. PubMed ID: 38498297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
    Pycha S; Trenti E; Mian C; Schwienbacher C; Hanspeter E; Palermo M; Pycha A; Danuser H; D'Elia C
    World J Urol; 2023 May; 41(5):1323-1328. PubMed ID: 36929411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial.
    Territo A; Gallioli A; Diana P; Boissier R; Fontana M; Gaya JM; Sanguedolce F; Calderón J; Piana A; Fontanet S; Algaba F; Palou J; Breda A
    J Urol; 2022 Sep; 208(3):570-579. PubMed ID: 35549312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does urinary cytology have a role in haematuria investigations?
    Tan WS; Sarpong R; Khetrapal P; Rodney S; Mostafid H; Cresswell J; Watson D; Rane A; Hicks J; Hellawell G; Davies M; Srirangam SJ; Dawson L; Payne D; Williams N; Brew-Graves C; Feber A; Kelly JD;
    BJU Int; 2019 Jan; 123(1):74-81. PubMed ID: 30003675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xpert® bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results.
    D'Elia C; Trenti E; Krause P; Pycha A; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Palermo M; Spedicato GA; Holl S; Pycha A
    Ther Adv Urol; 2022; 14():17562872221090320. PubMed ID: 35450126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
    Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples.
    Pierconti F; Martini M; Fiorentino V; Cenci T; Racioppi M; Foschi N; Di Gianfrancesco L; Sacco E; Rossi E; Larocca LM; Bassi PF
    Hum Pathol; 2021 Dec; 118():42-48. PubMed ID: 34582934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
    Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation study of the Paris system for reporting urinary (TPS) categories.
    Pierconti F; Martini M; Cenci T; Fiorentino V; Sacco E; Bientinesi R; Pugliese D; Iacovelli R; Schinzari G; Larocca LM; Bassi PF
    J Clin Pathol; 2021 Feb; 74(2):102-105. PubMed ID: 32527754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
    Pierconti F; Martini M; Fiorentino V; Cenci T; Capodimonti S; Straccia P; Sacco E; Pugliese D; Cindolo L; Larocca LM; Bassi PF
    Urol Oncol; 2021 Feb; 39(2):131.e17-131.e21. PubMed ID: 32773233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; Pycha S; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Spedicato GA; Vjaters E; Degener S; Pycha A; D'Elia C
    Cancer Cytopathol; 2020 May; 128(5):341-347. PubMed ID: 31977131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma.
    Messer J; Shariat SF; Brien JC; Herman MP; Ng CK; Scherr DS; Scoll B; Uzzo RG; Wille M; Eggener SE; Steinberg G; Terrell JD; Lucas SM; Lotan Y; Boorjian SA; Raman JD
    BJU Int; 2011 Sep; 108(5):701-5. PubMed ID: 21320275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma.
    Fojecki G; Magnusson A; Traxer O; Baard J; Osther PJS; Jaremko G; Seitz C; Knoll T; Giusti G; Brehmer M
    World J Urol; 2019 Nov; 37(11):2271-2278. PubMed ID: 30915526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer.
    Ragonese M; Gianfrancesco LD; Palermo G; Pierconti F; Martini M; Foti M; Bassi P; Racioppi M
    Clin Genitourin Cancer; 2022 Aug; 20(4):e271-e275. PubMed ID: 35871875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
    Trail M; Rahman MSW; Broadhurst WJ; Blackmur JP; Sharma A; Chew E; O'Donnell M; Keanie JY; Brush J; Taylor J; Phipps S; Thomas B; Mains EAA; McNeill SA; Leung S; Cutress ML; Laird A
    BJU Int; 2023 Jun; 131(6):755-762. PubMed ID: 36495480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.